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Introduction: Postmenopausal women with rheumatoid arthritis (RA) have increased risk of developing osteoporosis
due to chronic inflammation and estrogen deprivation. Collagen antibody-induced arthritis (CAIA), an experimental
polyarthritis model representing the effector phase of arthritis, is mainly mediated by the innate immune system.
Compared to the widely used collagen-induced arthritis model, CAIA is conveniently short and can be used in C57BL/6
mice, enabling studies with knock-out mice. However, the impact on bone of the CAIA model in C57BL/6 mice has
not previously been studied. Therefore, the aim of this study was to determine if CAIA can be used to study
postmenopausal arthritis-induced osteoporosis.
Methods: CAIA was induced by administration of collagen-type II antibodies and lipopolysaccharide to ovariectomized
female C57BL/6J mice. Control mice received lipopolysaccharide, but no antibodies. Nine days later, femurs were
collected for high-resolution micro-CT and histomorphometry. Serum was used to assess cartilage breakdown and
levels of complement. Frequencies of immune cell subsets from bone marrow and lymph nodes were analyzed by
flow cytometery.
Results: Trabecular bone mass was decreased and associated with increased number of osteoclasts per bone surface
in the CAIA model. Also, the frequency of interleukin-17+ cells in lymph nodes was increased in CAIA.
Conclusion: The present study show that CAIA, a short reproducible arthritis model that is compatible with C57BL/6
mice, is associated with increased number of osteoclasts and trabecular bone loss.Introduction
Rheumatoid arthritis (RA) is an autoimmune disease in
which chronic joint inflammation leads to cartilage and
bone destruction. In addition, about 50 % of female post-
menopausal RA patients also have generalized osteo-
porosis [1] and consequently increased risk of fractures.
The peak incidence of RA in women occurs at meno-
pause when estrogen levels drop [2, 3] and removal of
endogenously produced estrogens by ovariectomy in
mice leads to a more severe arthritis and increased bone
loss [4]. Collagen-induced arthritis (CIA) is widely used
to study arthritis-induced osteoporosis [4–6]. Unfortu-
nately, the susceptibility for CIA is poor in mice of
C57BL/6 background, the commonly used strain for* Correspondence: louise.grahnemo@gu.se
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creativecommons.org/publicdomain/zero/1.0/knockout models. It is therefore most relevant to find an
arthritis model that can be used to study arthritis-induced
osteoporosis in C57BL/6 mice. Collagen antibody-induced
arthritis (CAIA) is a short commercially available experi-
mental arthritis model representing only the effector
phase of arthritis [7] that is mainly mediated by the innate
immune system. An intravenous injection of anti-collagen
type II (anti-CII) antibodies, directed towards several
epitopes on CII in joint cartilage, followed by an intra-
peritoneal injection of lipopolysaccharide (LPS) rapidly
induces polyarthritis. Antibodies bound to cartilage acti-
vate the complement system and Fc-receptor-expressing
monocytes/macrophages. In addition, neutrophils that
produce proteinases and reactive oxygen species are re-
cruited [8–10]. Of note, autoantibodies reactive for CII are
also present in a large proportion of RA patients [11].
C57BL/6 mice are susceptible to CAIA, but thess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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has never previously been investigated. The aim of this
study was thus to determine whether CAIA is a suitable
model for studies of postmenopausal arthritis-induced
osteoporosis.Materials and methods
Mice
This study was approved by the ethical committee for ani-
mal experiments in Gothenburg. Female C57BL/6J mice
(Charles River Laboratories, Sulzfeld, Germany) were kept
under standard environmental conditions and fed soy-free
chow and tap water ad libitum. All mice in the experi-
ment, both in the non-arthritic group (“control”, n = 14)
and in the arthritic group (“CAIA”, n = 15), were ovariec-
tomized at 8 weeks of age as described previously [12].
Successful removal of ovaries was confirmed by weighing
uteri at termination of the experiment.Arthritis induction
Two weeks after ovariectomy, the ArthritoMab™ CII mAb
cocktail for C57BL/6 (8 mg/mouse; MD Biosciences
GmbH, Zürich, Switzerland) was injected intravenously to
induce arthritis (CAIA group). Non-arthritic control mice
received phosphate-buffered saline. Three days after anti-
body administration, 100 μg LPS (Escherichia coli 055:B5;
MD Biosciences) was injected intraperitoneally to CAIA
and control mice. Mice were randomly assigned to experi-
mental groups. The experiment was ended 9 days after
antibody administration. This day for termination was
chosen based on previous pilot studies showing that arth-
ritis incidence peaked at day 6 after antibody administra-
tion and that arthritis severity decreased after day 7.Arthritis evaluation
Arthritis incidence and severity were evaluated daily in a
blinded manner. Severity was graded 0–3 in each paw
(with a total maximum score of 12 per mouse) as fol-
lows: swelling in digits: 0.25 points per digit, maximum
1 point per paw; mild, intermediate, or severe swelling
in metacarpal/tarsal joints: 0.5, 0.75, or 1 points, res-
pectively; and mild, intermediate, or severe swelling in
carpal/tarsal joints: 0.5, 0.75, or 1 points, respectively.High-resolution micro-computed tomography
High-resolution micro-computed tomography (μCT) ana-
lyses were performed using an 1172 micro-CT model
(Bruker, Aartselaar, Belgium) as described previously [12].
Trabecular bone parameters were analyzed in the distal
metaphyseal region while the cortical bone parameters
were analyzed in the diaphyseal region of femur [12].Enzyme-linked immunosorbent assay
Sera were stored at −20 °C until use. Complement factor 3
(C3; Immunology Consultants Laboratory, Inc., Portland,
OR, USA), cartilage oligomeric matrix protein (COMP;
AnaMar AB, Gothenburg, Sweden), C-terminal telo-
peptides of type I collagen (CTX-I; Immunodiagnostics
Systems Ltd, Boldon, UK), and N-terminal propeptide of
type I procollagen (PINP; Immunodiagnostics Systems
Ltd) were measured by enzyme-linked immunosorbent
assay (ELISA) in serum diluted 1:50,000, 1:10, 1:2, and 1:1,
respectively, according to the manufacturer’s instructions.
The assay detection limits for C3, CTX-I, and PINP were
1.379 ng/ml, 2 ng/ml, and 7 ng/ml, respectively. The sen-
sitivity of the COMP ELISA was 0.02 U/l.
Histomorphometry
Tartrate-resistant acid phosphatase activity was demon-
strated in femurs as previously described by Toyosawa
et al. [13]. The number of osteoclasts (tartrate-resistant
acid phosphatase-positive nucleated cells on the bone
surface) in the distal femoral epiphysis was counted and
divided by the bone surface using a Nikon Eclipse 80i
microscope with Osteomeasure™ software (v.3.2.1.7;
Osteometrics Inc., Decatur, GA, USA).
Preparation of cells and flow cytometry analysis
Bone marrow was flushed from the femur using a syringe.
Lymph nodes draining the joints were mashed in a 70 μm
cell strainer. Single cell suspensions were stained for
surface markers using anti-CD3 Horizon V500 and anti-
CD11b Horizon V500 (Becton, Dickinson & Company
(BD), Franklin Lakes, NJ, USA), anti-CD4 fluorescein iso-
thiocyanate (FITC), anti-MCSF-R allophycocyanin (APC),
and anti-F4/80 FITC (BioLegend, San Diego, CA, USA)
antibodies. Lymphocytes were gated on singlet cells and
CD4+ T cells were defined as CD3+CD4+ cells. Preosteo-
clasts were gated on singlet cells and defined as CD11b
+F4/80+MCSF-R+ cells. For detection of interleukin (IL)-
17+ cells in lymph nodes, cells were stimulated with phor-
bol 12-myristate 13-acetate (50 ng/ml; Sigma), ionomycin
calcium salt (1 μg/ml; Sigma) and Golgiplug® (BD) for
4 hours at 37 °C and 5 % CO2, and stained intracellularly
with anti-IL-17A APC (eBioscience, Vienna, Austria).
Samples were run on a BD FACS Canto II and data were
analyzed using the Flow Jo 8.8.6 or 10.0.6 software (Three
Star Inc, Ashland, OR, USA).
Statistical analysis
Statistical analyses were performed using SPSS software
21.0 (IBM, Armonk, NY, USA). Student’s t test was used
for comparison of two independent groups. Logarithmic
transformations were used when appropriate to ensure
normal distribution of data. Experiments were termi-
nated on different days; variation between days was
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analysis of covariance. The log-rank test was used to
analyze arthritis incidence, and data are presented as
Kaplan–Meier curves. The area under the curve for
arthritis severity versus time was calculated for each
mouse by the trapezoidal method:
Area ≈ 0:5 y0 þ y1ð ÞΔxþ 0:5 y1 þ y2ð ÞΔxþ 0:5 y2 þ y3ð ÞΔxþ …
where Δx is the time between arthritis assessment and
y0, y1, y2, y3, etc. is the arthritis severity score for day 0,
1, 2, 3, etc. Since the scoring was performed using an
ordinal scale, comparisons between groups were ana-
lyzed by non-parametric Mann–Whitney test. Differ-
ences in n are due to lack of sample, sickness, or
laboratory errors. All tests are two sided. Data are pre-
sented as mean + standard error of the mean, unless
otherwise stated. p <0.05 was considered significant.
Results
Arthritis development in CAIA
Arthritis incidence in CAIA mice was 73 %, while no
control mice developed arthritis (Fig. 1a). Arthritis sever-
ity in CAIA mice was mild and peaked on day 9 (Fig. 1b).
Arthritis developed most frequently in the metacarpal/
metatarsal and carpal/tarsal joints, and all mice with
arthritis had two or more swollen joint regions (metacar-
pal, metatarsal, carpal, tarsal, and/or one or more swol-
len digits at day 9) (data not shown). The complement
system is important in arthritis development in CAIA
[14], and the serum C3 levels were increased by 31 % in
CAIA mice compared with controls (Fig. 1c). A common
feature of RA is cartilage destruction, and serum levels
of COMP—a biomarker of cartilage degradation—wereFig. 1 Increased serum levels of C3 and COMP in CAIA mice. C57BL/6 mice
(CAIA) or LPS alone (control). The experiment was terminated 9 days after
(n = 15) mice. Log-rank test (***p <0.001). b Arthritis severity in control (n = 15
curve was calculated for each group and analyzed by Mann–Whitney test (***
were measured at day 9 after arthritis induction in control (n = 14) and CAIA (
CAIA collagen-antibody induced arthritis, COMP cartilage oligomeric matrix princreased by 36 % in CAIA mice compared with controls
(Fig. 1d).Trabecular, but not cortical, bone loss in CAIA
Generalized bone loss has not previously been studied in
the CAIA model. Although the model is very short
(9 days), CAIA mice had 34 % lower trabecular bone
volume/tissue volume in the distal femoral metaphysis
compared with controls (Fig. 2a). Trabecular thickness
and trabecular number were decreased by 9 % and 28 %,
respectively (Fig. 2b, c), while trabecular spacing was in-
creased by 6 % (Fig. 2d), demonstrating a robust effect
of CAIA on trabecular bone loss. However, neither cor-
tical thickness (Fig. 2e) or cortical area in the diaphyseal
region of femur (data not shown) was affected in CAIA.Increased osteoclast number in femurs of CAIA mice
A possible explanation for the trabecular bone loss in
CAIA is increased number and function of osteoclasts.
The number of osteoclasts per bone surface in the distal
femoral epiphysis was increased by 81 % in CAIA mice
compared with control mice (Fig. 3a). In addition, there
was a tendency (p = 0.064) for increased frequency of
preosteoclasts in the bone marrow of CAIA mice
(Fig. 3b).
Although we observed an increase in the number of
osteoclasts per bone surface, we did not find any dif-
ference in either the bone resorption marker CTX-I
(control mice: 28.5 ± 1.4 vs. CAIA mice: 29.4 ± 1.3 ng/ml,
n = 14–15/group, p = 0.643, Student’s t test) or the bone
formation marker PINP (control mice: 103.3 ± 3.3 vs.
CAIA mice: 90.6 ± 7.0 ng/ml, n = 14–15/group, p = 0.121,
Student’s t test).were ovariectomized and subjected to LPS + collagen antibodies
arthritis induction. a Arthritis incidence in control (n = 15) and CAIA
) and CAIA (n = 15) mice. Data are median + upper range. Area under the
p <0.001). Serum levels of c (C3; ***p <0.001) and d COMP (***p <0.001)
n = 15) mice. Student’s t test c, d, on log data c. C3 complement factor 3,
otein, LPS lipopolysaccharide
a b c d e 
Fig. 2 CAIA results in trabecular, but not cortical, bone loss. C57BL/6 mice were ovariectomized and subjected to LPS + collagen antibodies
(CAIA) or LPS alone (control). The experiment was terminated 9 days after arthritis induction. a Trabecular bone volume as percent of tissue
volume (BV/TV) (**p = 0.005), b trabecular thickness (Tb.Th) (**p = 0.006), c trabecular number (Tb.N) (*p = 0.011), and d trabecular separation
(Tb.Sp) (*p = 0.024) in the distal metaphyseal region as well as e cortical thickness (Ct.Th) (p = 0.358) in the diaphyseal region of femur was
analyzed by μCT in CAIA (n = 7) and control (n = 7) mice. Student’s t test a–e, on log data a, b, c, e. CAIA collagen-antibody induced arthritis,
LPS lipopolysaccharide
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T cells, and in particular the Th17 cell associated cyto-
kine IL-17, is involved in the pathology of arthritis-
induced osteoporosis [15]. The frequency of T cells and
IL-17-producing cells in lymph nodes was therefore ana-
lyzed by flow cytometry. The CD4+ T-cell frequency was
unaffected by CAIA, but IL-17+ cells were increased
(Fig. 3c, d).
Discussion
This study reveals for the first time that CAIA can be used
as a model to study arthritis-induced generalized bone
loss. An increased number of osteoclasts per bone surface
in CAIA provides a reasonable explanation for trabecular
bone loss. CII antibody deposition in articular cartilage
leads to activation of Fc-receptor-expressing cells; for
example, macrophages that produce proinflammatory
cytokines such as tumor necrosis factor and IL-1β [9].



































Fig. 3 Increase in osteoclasts in CAIA. C57BL/6 mice were ovariectomized and
The experiment was terminated 9 days after arthritis induction. a Number of
in control (n = 6) and CAIA (n = 5) mice, b frequency of preosteoclasts (% CD1
(n = 11) and CAIA (n = 13) mice, c frequency of CD4+ T cells (of lymphocytes)
IL-17+ cells (of lymphocytes) (*p = 0.049) in control (n = 14) and CAIA (n = 14)
b, c, and d, on log data b, d. CAIA collagen-antibody induced arthritis, IL interdifferentiation [16]. Moreover, the Th17-associated cyto-
kine IL-17 induces receptor activator of nuclear factor
kappa-B ligand (RANKL) expression on osteoblasts and
synovial fibroblasts, resulting in increased in vitro osteo-
clastogenesis [17]. Indeed, in this study increased levels of
IL-17+ cells were detected in lymph nodes draining the
joints in CAIA. The role of IL-17 specifically in CAIA is
fairly unstudied; however, IL-17 knockout mice develop
less severe arthritis than wildtype controls in the K/BxN
serum transfer arthritis model [18]. Induction of CAIA is
T-cell independent, although transfer of CII-specific T
cells exaggerates arthritis [19]. We thus speculate that
Th17 as well as other cells might be producers of IL-17 in
CAIA. Indeed, it has become increasingly clear that innate
cells can also produce IL-17 in arthritic disease [18, 20]. In
addition, the complement system is also important in
arthritis development in the CAIA model [14]. Indeed,
we found elevated levels of C3 in serum of CAIA mice.


























subjected to LPS + collagen antibodies (CAIA) or LPS alone (control).
osteoclasts (**p = 0.009) in the distal femoral epiphysis per bone surface
1b+F4/80+MCSF-R+ cells of CD11b+ cells) in bone marrow from control
(p = 0.227) in control (n = 15) and CAIA (n = 14) mice, and d frequency of
mice, in draining lymph nodes. Student’s t test a. Analysis of covariance
leukin, LPS lipopolysaccharide
Grahnemo et al. Arthritis Research & Therapy  (2015) 17:189 Page 5 of 6osteoclastogenesis [21], and could thus be another pos-
sible mediator of the low trabecular bone in CAIA mice.
However, the control mice also had quite high levels of
serum C3, possibly explained by the LPS injection, since
LPS stimulates C3 synthesis [22]. More studies on cellular
and molecular mechanisms of CAIA are thus required to
fully understand the link between CII antibody-induced
joint inflammation and generalized bone loss.
In contrast to this study, we have previously been un-
able to detect generalized bone loss in CAIA [23]. How-
ever, that study was performed in DBA/1 mice with a
different antibody cocktail and bone measurement were
performed with peripheral quantitative computer tom-
ography (pQCT). In this study, μCT was used to investi-
gate generalized bone loss, and this technique has also
previously been successful to detect local bone erosions
and paw swelling in CAIA [24]. CAIA resulted in signifi-
cant alterations in trabecular bone parameters, but not
cortical. The study is probably too short to detect
changes in cortical bone, which has a slower bone turn-
over than trabecular bone [25]. However, the arthritis in-
duced in the CAIA model quickly declines [26] and an
extension of the study might therefore not allow estab-
lishment of a cortical bone phenotype.
Conclusion
CAIA is a short convenient model of arthritis-induced
osteoporosis in C57BL/6 mice, enabling use of transgenic
mice, and serves as a new valuable tool in osteoimmu-
nology research.
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